MC-DUO(VP) Dual System Packaging Leak Detector
The MC-DUO(VP) is a non-destructive leak detection system designed for both vacuum decay and pressure decay testing methods. The system is easy to switch between these two modes. This versatile equipment is ideal for drug development, QC lab, and production line.
Fill in the information
Test Method
Application
Flexible packaging
Infusion soft bag, etc.
Rigid packaging
Vials for filling powder, lyophilized or medicinal liquid, pre-filled syringes, ampoules, infusion bottles, etc.
Features
01
Utilizes imported high-precision sensors for excellent sensitivity (down to 1 μm), fast cycle times, and high repeatability.
02
Employs non-destructive technology, safeguarding product and package stability.
03
Developed in accordance with the FDA-recognized ASTM F2338 test standard.
04
Compliant with FDA 21 CFR Part 11 requirements, featuring access controls, audit trail, and electronic signature capabilities.
05
Enables quick, user-friendly switching between vacuum and pressure decay modes.
Technical Specifications
|
Sensors |
Imported dual-sensor system |
|
Pressure Resolution |
0.1 Pa |
|
Vacuum/Pressure Source |
Vacuum: External pump; Pressure: External air compressor |
|
Validation Package |
IQ/OQ Documentation Available |
|
Calibration |
Via micro-flow meter or standard leak artifacts |
|
Dimensions |
440 × 410 × 270 mm(LxWxH) |
|
Weight |
19 kg |
|
Power Supply |
100-240 VAC, 50/60 Hz |
More Information
What is the difference between probabilistic and deterministic test methods?
Probabilistic and deterministic methods differ fundamentally in principle, output, and reliability.
- Probabilistic methods (e.g., microbial ingress, dye ingress) – Results are influenced by variable factors. Output is typically qualitative or semi‑quantitative, and cannot precisely locate or size leaks. They provide probability‑based, indirect evidence of integrity.
- Deterministic methods (e.g., vacuum decay, laser-based headspace analysis) – Based on physical principles, measuring quantifiable parameters to directly detect leaks. Results are objective, quantitative, and highly repeatable, enabling calibration, trend analysis, and statistical process control. They provide a higher level of assurance and reliability.
What is Container Closure Integrity (CCI)?
Container Closure Integrity (CCI) refers to the ability of a packaging system to prevent product loss, microbial ingress, and entry of gases (oxygen, air, water vapor, etc.) or other substances, thereby ensuring that the drug product remains safe and meets quality standards throughout its shelf life.
For injectable packaging systems, CCI requirements fall into three categories:
1. maintain sterility and product composition without the need to preserve headspace gas;
2. maintain sterility, product composition, and headspace gas;
3. for multi-dose containers that must maintain sterility after opening – prevent microbial ingress and product leakage during use. CCI studies for injectable products should be tailored to product characteristics.
A packaging system is generally considered to have acceptable CCI when it has passed or is capable of passing a microbial challenge test. In a broader sense, CCI means the absence of any leakage that could compromise drug quality. Based on scientific research and risk assessment, the Maximum Allowable Leakage Limit (MALL) should be determined considering packaging composition and assembly, product contents, and the environment to which the product may be exposed over its lifecycle. If a package’s leakage does not exceed its MALL, the closure system is considered integral.
Which regulations and guidelines address Container Closure Integrity?
Key regulatory and technical guidance documents for CCI include:
- EU GMP Annex 1 – Mandates container closure integrity verification and testing for terminally sterilized products, with differentiated requirements based on container type.
- USP <1207> – A comprehensive technical guide widely accepted as the industry standard, systematically describing test method categories, selection, validation, and lifecycle application. FDA guidance also permits physical CCI testing as an alternative to some sterility tests in stability studies.
- China NMPA – "Technical Guideline for Packaging System Integrity Study of Chemical Injectables (Trial)" – Signals increasing regulatory attention and alignment with international standards.
Related Products
